Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Parkinson's Disease

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 89 articles: HTML format

Single Articles

April 2024
1. GONZALEZ-LATAPI P, Bustos B, Dong S, Lubbe S, et al
   Alterations in Blood Methylome as Potential Epigenetic Biomarker in Sporadic Parkinson's Disease.
   Ann Neurol. 2024 Apr 2. doi: 10.1002/ana.26923.
   PubMed     Abstract available
   
   
   
2. POST E, Hall DA, Bloem BR
   Reply to "An Apple a Day Will Not Keep the (Parkinson's Disease) Doctor at Bay!".
   Ann Neurol. 2024 Apr 1. doi: 10.1002/ana.26937.
   PubMed    
   
   
   
3. KHANI M, Cerquera-Cleves C, Kekenadze M, Wild Crea P, et al
   Towards a Global View of Parkinson's Disease Genetics.
   Ann Neurol. 2024 Apr 1. doi: 10.1002/ana.26905.
   PubMed     Abstract available
   
   
   March 2024
4. BOOGERS A, Fasano A, Lang A
   An Apple a Day Will Not Keep the (Parkinson Disease) Doctor at Bay!
   Ann Neurol. 2024 Mar 30. doi: 10.1002/ana.26936.
   PubMed    
   
   
   
5. KLUGE A, Borsche M, Streubel-Gallasch L, Gul T, et al
   alpha-Synuclein Pathology in PRKN-Linked Parkinson's Disease: New Insights from a Blood-Based Seed Amplification Assay.
   Ann Neurol. 2024 Mar 28. doi: 10.1002/ana.26917.
   PubMed     Abstract available
   
   
   
6. DEL BENE VA, Martin RC, Brinkerhoff SA, Olson JW, et al
   Differential Cognitive Effects of Unilateral Subthalamic Nucleus Deep Brain Stimulation for Parkinson's Disease.
   Ann Neurol. 2024 Mar 19. doi: 10.1002/ana.26903.
   PubMed     Abstract available
   
   
   December 2023
7. WIESMAN AI, da Silva Castanheira J, Fon EA, Baillet S, et al
   Alterations of cortical structure and neurophysiology in Parkinson's disease are aligned with neurochemical systems.
   Ann Neurol. 2023 Dec 26. doi: 10.1002/ana.26871.
   PubMed     Abstract available
   
   
   
8. REYNOSO A, Torricelli R, Jacobs BM, Shi J, et al
   Gene-environment interactions for Parkinson's disease.
   Ann Neurol. 2023 Dec 19. doi: 10.1002/ana.26852.
   PubMed     Abstract available
   
   
   November 2023
9. ZHOU L, Li SX, Chau SW, Huang B, et al
   Altered impulsivity across drug-naive parkinsonism, isolated REM sleep behavior disorder, and their high-risk relatives.
   Ann Neurol. 2023 Nov 23. doi: 10.1002/ana.26836.
   PubMed     Abstract available
   
   
   
10. CHUN MY, Chung SJ, Kim SH, Park CW, et al
    Hippocampal Perfusion Affects Motor and Cognitive Functions in Parkinson's Disease: An Early-Phase (18) F-FP-CIT PET Study.
    Ann Neurol. 2023 Nov 14. doi: 10.1002/ana.26827.
    PubMed     Abstract available
    
    
    August 2023
11. MOHAMMADZADEH N, Tung GA, Prakash P, Alhusaini S, et al
    Parkinsonism: A Rare Complication of Cerebral Toxoplasmosis.
    Ann Neurol. 2023 Aug 30. doi: 10.1002/ana.26777.
    PubMed    
    
    
    
12. KANG X, Ploner A, Roelstraete B, Ludvigsson JF, et al
    Risk of Parkinson's disease in celiac disease: A Swedish population-based study.
    Ann Neurol. 2023 Aug 26. doi: 10.1002/ana.26780.
    PubMed     Abstract available
    
    
    June 2023
13. HE P, Shi L, Li Y, Duan Q, et al
    The Association of the Glymphatic Function with Parkinson's Disease Symptoms: Neuroimaging Evidence from Longitudinal and Cross-sectional Studies.
    Ann Neurol. 2023 Jun 28. doi: 10.1002/ana.26729.
    PubMed     Abstract available
    
    
    
14. NIETHAMMER M, Tang CC, Jamora RDG, Vo A, et al
    A network imaging biomarker of X-linked dystonia-parkinsonism.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26732.
    PubMed     Abstract available
    
    
    
15. PALACIOS N, Wilkinson J, Bjornevik K, Schwarzschild MA, et al
    Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes.
    Ann Neurol. 2023 Jun 14. doi: 10.1002/ana.26719.
    PubMed     Abstract available
    
    
    May 2023
16. HACKER ML, Rajamani N, Neudorfer C, Hollunder B, et al
    Connectivity Profile for Subthalamic Nucleus Deep Brain Stimulation in Early-Stage Parkinson's Disease.
    Ann Neurol. 2023 May 13. doi: 10.1002/ana.26674.
    PubMed     Abstract available
    
    
    
17. WILKINS KB, Kehnemouyi YM, Petrucci MN, Anderson RW, et al
    Bradykinesia and Its Progression Are Related to Interhemispheric Beta Coherence.
    Ann Neurol. 2023;93:1029-1039.
    PubMed     Abstract available
    
    
    April 2023
18. NEDELEC T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, et al
    A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.
    Ann Neurol. 2023 Apr 25. doi: 10.1002/ana.26670.
    PubMed     Abstract available
    
    
    March 2023
19. LIU B, Svenningsson P, Ludvigsson JF, Lundholm C, et al
    beta2-adrenoreceptor agonists, montelukast, and Parkinson's disease risk.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26638.
    PubMed     Abstract available
    
    
    
20. LANORE A, Casse F, Tesson C, Courtin T, et al
    Differences in survival across monogenic forms of Parkinson's disease.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26636.
    PubMed     Abstract available
    
    
    
21. TROPEA TF, Albuja I, Cousins KAQ, Irwin DJ, et al
    Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia.
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26635.
    PubMed    
    
    
    
22. YOUNCE JR, Martin WRW, Perlmutter JS
    Reply to "Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia".
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26630.
    PubMed    
    
    
    February 2023
23. JACOB MA, Cai M, Bergkamp M, Darweesh SKL, et al
    Cerebral Small Vessel Disease Progression Increases Risk of Incident Parkinsonism.
    Ann Neurol. 2023 Feb 10. doi: 10.1002/ana.26615.
    PubMed     Abstract available
    
    
    
24. MIYAMOTO K, Saiki S, Matsumoto H, Suzuki A, et al
    Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD.
    Ann Neurol. 2023;93:303-316.
    PubMed     Abstract available
    
    
    January 2023
25. BLOEM BR, Post E, Hall D
    An Apple a day to keep the Parkinson's disease doctor away?
    Ann Neurol. 2023 Jan 27. doi: 10.1002/ana.26612.
    PubMed     Abstract available
    
    
    
26. BILLINGSLEY KJ, Ding J, Alvarez Jerez P, Illarionova A, et al
    Genome-wide analysis of Structural Variants in Parkinson's Disease.
    Ann Neurol. 2023 Jan 25. doi: 10.1002/ana.26608.
    PubMed     Abstract available
    
    
    
27. HANSSEN H, Diesta CCE, Heldmann M, Dy J, et al
    Basal Ganglia Atrophy as a Marker for Prodromal X-linked Dystonia-Parkinsonism.
    Ann Neurol. 2023 Jan 16. doi: 10.1002/ana.26606.
    PubMed     Abstract available
    
    
    
28. RAY NJ, Kanel P, Bohnen NI
    Atrophy of the cholinergic basal forebrain can detect presynaptic cholinergic loss in Parkinson's disease.
    Ann Neurol. 2023 Jan 4. doi: 10.1002/ana.26596.
    PubMed     Abstract available
    
    
    November 2022
29. DE BARTOLO MI, Vivacqua G, Belvisi D, Mancinelli R, et al
    A combined panel of salivary biomarkers in de novo Parkinson's Disease.
    Ann Neurol. 2022 Nov 16. doi: 10.1002/ana.26550.
    PubMed     Abstract available
    
    
    
30. MARTIN WRW, Younce JR, Campbell MC, Racette BA, et al
    Neocortical Lewy body pathology parallels Parkinson's dementia, but not always.
    Ann Neurol. 2022 Nov 4. doi: 10.1002/ana.26542.
    PubMed     Abstract available
    
    
    
31. GARRIDO A, Perez-Sisques L, Simonet C, Campoy-Campos G, et al
    Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers.
    Ann Neurol. 2022;92:888-894.
    PubMed     Abstract available
    
    
    October 2022
32. SCHIRINZI T, Maftei D, Passali FM, Grillo P, et al
    Olfactory neuron Prokineticin-2 as a potential target in Parkinson's disease.
    Ann Neurol. 2022 Oct 11. doi: 10.1002/ana.26526.
    PubMed     Abstract available
    
    
    
33. RASCHELLA F, Scafa S, Puiatti A, Martin Moraud E, et al
    Actigraphy enables home screening of REM behavior disorder in Parkinson disease.
    Ann Neurol. 2022 Oct 4. doi: 10.1002/ana.26517.
    PubMed     Abstract available
    
    
    September 2022
34. FUNG WK, Cohn M, Lang AE, Fasano A, et al
    Precision vs. Personalized DBS for GBA-related Parkinson disease.
    Ann Neurol. 2022 Sep 2. doi: 10.1002/ana.26499.
    PubMed    
    
    
    August 2022
35. AL-MUBARAK B, Ahmed Nour M, Schumacher-Schuh A, Bandres-Ciga S, et al
    Globalizing research towards diverse representation in Alzheimer's and Parkinson's disease.
    Ann Neurol. 2022 Aug 24. doi: 10.1002/ana.26483.
    PubMed    
    
    
    
36. MARIN-LAHOZ J, Martinez-Horta S, Pagonabarraga J, Horta-Barba A, et al
    Predicting Impulse Control Disorders in Parkinson's disease through incentive biomarkers.
    Ann Neurol. 2022 Aug 19. doi: 10.1002/ana.26486.
    PubMed     Abstract available
    
    
    
37. PERINAN MT, Brolin K, Bandres-Ciga S, Blauwendraat C, et al
    Effect modification between genes and environment, and Parkinson's disease risk.
    Ann Neurol. 2022 Aug 1. doi: 10.1002/ana.26467.
    PubMed     Abstract available
    
    
    July 2022
38. KENT DM, Leung LY, Puttock EJ, Wang AY, et al
    Development of Parkinson's disease and its relationship with incidentally-discovered white matter disease and covert brain infarction in a real-world cohort.
    Ann Neurol. 2022 Jul 22. doi: 10.1002/ana.26458.
    PubMed     Abstract available
    
    
    
39. BOLLIRI C, Fontana A, Cereda E, Barichella M, et al
    Gut Microbiota in Monozygotic Twins Discordant for Parkinson's Disease.
    Ann Neurol. 2022 Jul 19. doi: 10.1002/ana.26454.
    PubMed     Abstract available
    
    
    June 2022
40. PRANGE S, Lin Z, Nourredine M, Danaila T, et al
    Limbic stimulation drives mania in STN-DBS in Parkinson disease: a prospective study.
    Ann Neurol. 2022 Jun 15. doi: 10.1002/ana.26434.
    PubMed     Abstract available
    
    
    
41. PAL G, Mangone G, Ouyang B, Ehrlich D, et al
    Reply to: Cognitive effects of deep brain stimulation in GBA-related Parkinson's disease.
    Ann Neurol. 2022 Jun 10. doi: 10.1002/ana.26433.
    PubMed    
    
    
    
42. WEILL C, Gallant A, Lintsky E, Dienstag A, et al
    Cognitive effects of deep brain stimulation in GBA-related Parkinson's disease.
    Ann Neurol. 2022 Jun 10. doi: 10.1002/ana.26432.
    PubMed    
    
    
    May 2022
43. LIU H, Dehestani M, Blauwendraat C, Makarious MB, et al
    Polygenic resilience modulates the penetrance of Parkinson's disease genetic risk factors.
    Ann Neurol. 2022 May 22. doi: 10.1002/ana.26416.
    PubMed     Abstract available
    
    
    
44. HUANG Y, Liu Z, Li N, Tian C, et al
    Parkinson's disease derived exosomes aggravate neuropathology in SNCA*A53T mice.
    Ann Neurol. 2022 May 21. doi: 10.1002/ana.26421.
    PubMed     Abstract available
    
    
    
45. SHEN J, Amari N, Zack R, Skrinak RT, et al
    Plasma MIA, CRP, and albumin predict cognitive decline in Parkinson's Disease.
    Ann Neurol. 2022 May 20. doi: 10.1002/ana.26410.
    PubMed     Abstract available
    
    
    April 2022
46. CRAMER SW, Do TH, Palzer EF, Naik A, et al
    Persistent racial disparities in deep brain stimulation for Parkinson's disease.
    Ann Neurol. 2022 Apr 19. doi: 10.1002/ana.26378.
    PubMed     Abstract available
    
    
    
47. FURUKAWA K, Shima A, Kambe D, Nishida A, et al
    Motor progression and nigrostriatal neurodegeneration in Parkinson's disease.
    Ann Neurol. 2022 Apr 15. doi: 10.1002/ana.26373.
    PubMed     Abstract available
    
    
    February 2022
48. MONTENEGRO P, Pueyo M, Lorenzo JN, Villar MD, et al
    A secretory vesicle failure in Parkinson's disease occurs in human platelets.
    Ann Neurol. 2022 Feb 28. doi: 10.1002/ana.26335.
    PubMed     Abstract available
    
    
    January 2022
49. TOSSERAMS A, Weerdesteyn V, Bal T, Bloem BR, et al
    Cortical correlates of gait compensation strategies in Parkinson's disease.
    Ann Neurol. 2022 Jan 24. doi: 10.1002/ana.26306.
    PubMed     Abstract available
    
    
    
50. PAL G, Mangone G, Hill EJ, Ouyang B, et al
    Parkinson disease and STN-DBS: cognitive effects in GBA mutation carriers.
    Ann Neurol. 2022 Jan 4. doi: 10.1002/ana.26302.
    PubMed     Abstract available
    
    
    December 2021
51. JOHANSSON ME, Cameron IGM, van der Kolk NM, De Vries NM, et al
    Aerobic exercise alters brain function and structure in Parkinson's disease a randomized controlled trial.
    Ann Neurol. 2021 Dec 24. doi: 10.1002/ana.26291.
    PubMed     Abstract available
    
    
    November 2021
52. VILLANUEVA EB, Tresse E, Liu Y, Duarte JN, et al
    Neuronal TNFalpha, Not alpha-Syn, Underlies PDD-Like Disease Progression in IFNbeta-KO Mice.
    Ann Neurol. 2021;90:789-807.
    PubMed     Abstract available
    
    
    August 2021
53. ZHANG C, Lai Y, Li J, He N, et al
    Subthalamic and pallidal stimulations in patients with Parkinson's disease: common and dissociable connections.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26199.
    PubMed     Abstract available
    
    
    
54. VERGER A, Grimaldi S, Ribeiro MJ, Frismand S, et al
    SPECT/PET molecular imaging for parkinsonism: a fast-developing field.
    Ann Neurol. 2021 Aug 2. doi: 10.1002/ana.26187.
    PubMed     Abstract available
    
    
    July 2021
55. TAN EK
    Genetic studies of Parkinson's & Alzheimer's disease in Latinos/Hispanics: New Insights & Challenges.
    Ann Neurol. 2021 Jul 26. doi: 10.1002/ana.26179.
    PubMed    
    
    
    
56. WEISS D, Volkmann J, Fasano A, Kuhn A, et al
    Neurology Grand Rounds: Changing gears - DBS for dopaminergic desensitization in Parkinson's disease?
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26164.
    PubMed     Abstract available
    
    
    
57. LOESCH DP, Horimoto ARVR, Heilbron K, Sarihan EI, et al
    Characterizing the Genetic Architecture of Parkinson's Disease in Latinos.
    Ann Neurol. 2021 Jul 6. doi: 10.1002/ana.26153.
    PubMed     Abstract available
    
    
    June 2021
58. DARVISH H, Azcona LJ, Taghavi S, Firouzabadi SG, et al
    ANXA1 with anti-inflammatory properties might contribute to parkinsonism.
    Ann Neurol. 2021 Jun 28. doi: 10.1002/ana.26148.
    PubMed     Abstract available
    
    
    
59. SINGER W, Schmeichel AM, Shahnawaz M, Schmelzer JD, et al
    Alpha-Synuclein Oligomers and Neurofilament Light Chain Predict Phenoconversion of Pure Autonomic Failure.
    Ann Neurol. 2021;89:1212-1220.
    PubMed     Abstract available
    
    
    May 2021
60. HEINZEL S, Aho VTE, Suenkel U, von Thaler AK, et al
    Gut microbiome signatures of risk and prodromal markers of Parkinson's disease.
    Ann Neurol. 2021 May 22. doi: 10.1002/ana.26128.
    PubMed     Abstract available
    
    
    
61. ALBIN RL, Muller MLTM, Bohnen NI, Spino C, et al
    alpha4beta2(*) Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders.
    Ann Neurol. 2021 May 11. doi: 10.1002/ana.26102.
    PubMed     Abstract available
    
    
    
62. LAI D, Alipanahi B, Fontanillas P, Schwantes-An TH, et al
    Genome-wide association studies of LRRK2 modifiers of Parkinson's disease.
    Ann Neurol. 2021 May 2. doi: 10.1002/ana.26094.
    PubMed     Abstract available
    
    
    
63. KLEIN C, Konig IR
    Exploring uncharted territory: genetically determined sex differences in Parkinson's disease.
    Ann Neurol. 2021 May 2. doi: 10.1002/ana.26091.
    PubMed    
    
    
    April 2021
64. BLAUWENDRAAT C, Iwaki H, Makarious MB, Bandres-Ciga S, et al
    Investigation of Autosomal Genetic Sex Differences in Parkinson's disease.
    Ann Neurol. 2021 Apr 26. doi: 10.1002/ana.26090.
    PubMed     Abstract available
    
    
    
65. RUSZ J, Hlavnicka J, Novotny M, Tykalova T, et al
    Speech biomarkers in rapid eye movement sleep behaviour disorder and Parkinson's disease.
    Ann Neurol. 2021 Apr 15. doi: 10.1002/ana.26085.
    PubMed     Abstract available
    
    
    March 2021
66. ROSEBRAUGH M, Voight EA, Moussa EM, Jameel F, et al
    Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson's disease.
    Ann Neurol. 2021 Mar 26. doi: 10.1002/ana.26073.
    PubMed     Abstract available
    
    
    
67. ELIAS GJB, Boutet A, Joel SE, Germann J, et al
    Probabilistic Mapping of Deep Brain Stimulation: Insights from 15 Years of Therapy.
    Ann Neurol. 2021;89:426-443.
    PubMed     Abstract available
    
    
    February 2021
68. LE GUEN Y, Napolioni V, Belloy ME, Yu E, et al
    Common X-chromosome variants are associated with Parkinson's disease risk.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26051.
    PubMed     Abstract available
    
    
    
69. JENSEN MP, Jacobs BM, Dobson R, Bandres-Ciga S, et al
    Lower lymphocyte count is associated with increased risk of Parkinson's disease.
    Ann Neurol. 2021 Feb 2. doi: 10.1002/ana.26034.
    PubMed     Abstract available
    
    
    
70. RAHAYEL S, Postuma RB, Montplaisir J, Misic B, et al
    A Prodromal Brain-Clinical Pattern of Cognition in Synucleinopathies.
    Ann Neurol. 2021;89:341-357.
    PubMed     Abstract available
    
    
    
71. STANG CD, Mullan AF, Hajeb M, Camerucci E, et al
    Timeline of Rapid Eye Movement Sleep Behavior Disorder in Overt Alpha-Synucleinopathies.
    Ann Neurol. 2021;89:293-303.
    PubMed     Abstract available
    
    
    January 2021
72. ANDERSEN MS, Bandres-Ciga S, Reynolds RH, Hardy J, et al
    Heritability enrichment implicates microglia in Parkinson's disease pathogenesis.
    Ann Neurol. 2021 Jan 27. doi: 10.1002/ana.26032.
    PubMed     Abstract available
    
    
    December 2020
73. YAU WY, Sullivan R, Rocca C, Cali E, et al
    NOTCH2NLC Intermediate-length Repeat Expansion and Parkinson's Disease in Patients of European Descent.
    Ann Neurol. 2020 Dec 30. doi: 10.1002/ana.26003.
    PubMed    
    
    
    
74. SHI CH, Fan Y, Xu YM
    Reply to "NOTCH2NLC Intermediate-length Repeat Expansion and Parkinson's Disease".
    Ann Neurol. 2020 Dec 30. doi: 10.1002/ana.26005.
    PubMed    
    
    
    
75. CAVALLIERI F, Fraix V, Bove F, Mulas D, et al
    Predictors of long-term outcome of subthalamic stimulation in Parkinson disease.
    Ann Neurol. 2020 Dec 21. doi: 10.1002/ana.25994.
    PubMed     Abstract available
    
    
    
76. TAN AH, Chong CW, Lim SY, Yap IKS, et al
    Gut microbial ecosystem in Parkinson's disease: New clinico-biological insights from multi-omics.
    Ann Neurol. 2020 Dec 3. doi: 10.1002/ana.25982.
    PubMed     Abstract available
    
    
    
77. SHEN L, Jiang C, Hubbard CS, Ren J, et al
    Subthalamic Nucleus Deep Brain Stimulation Modulates 2 Distinct Neurocircuits.
    Ann Neurol. 2020;88:1178-1193.
    PubMed     Abstract available
    
    
    November 2020
78. LEE JY, Ahn J, Shin J, Jeon B, et al
    Parafovea change and dopamine loss in the retina with Parkinson's disease.
    Ann Neurol. 2020 Nov 24. doi: 10.1002/ana.25972.
    PubMed    
    
    
    October 2020
79. KIM CY, Wirth T, Hubsch C, Nemeth AH, et al
    Reply to "PPP2R5D genetic mutations and early-onset parkinsonism".
    Ann Neurol. 2020 Oct 24. doi: 10.1002/ana.25945.
    PubMed    
    
    
    
80. MURUETA-GOYENA A, Del Pino R, Galdos M, Arana B, et al
    Retinal thickness predicts the risk of cognitive decline in Parkinson's disease.
    Ann Neurol. 2020 Oct 24. doi: 10.1002/ana.25944.
    PubMed     Abstract available
    
    
    
81. DULOVIC-MAHLOW M, Konig IR, Trinh J, Diaw SH, et al
    Discordant monozygotic Parkinson disease twins: Role of mitochondrial integrity.
    Ann Neurol. 2020 Oct 23. doi: 10.1002/ana.25942.
    PubMed     Abstract available
    
    
    
82. WALKER IM, Riboldi GM, Drummond P, Saade-Lemus S, et al
    PPP2R5D genetic mutations and early-onset parkinsonism.
    Ann Neurol. 2020 Oct 23. doi: 10.1002/ana.25943.
    PubMed    
    
    
    
83. ESPAY AJ, Marsili L, Mahajan A, Sturchio A, et al
    Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25923.
    PubMed     Abstract available
    
    
    
84. SHI CH, Fan Y, Yang J, Yuan YP, et al
    NOTCH2NLC Intermediate-length Repeat Expansions are Associated with Parkinson's Disease.
    Ann Neurol. 2020 Oct 5. doi: 10.1002/ana.25925.
    PubMed     Abstract available
    
    
    
85. LESAGE S, Lunati A, Houot M, Romdhan SB, et al
    Characterization of Recessive Parkinson Disease in a Large Multicenter Study.
    Ann Neurol. 2020;88:843-850.
    PubMed     Abstract available
    
    
    September 2020
86. NUBER S, Nam AY, Rajsombath MM, Cirka H, et al
    A stearoyl-CoA desaturase inhibitor prevents multiple Parkinson's disease-phenotypes in alpha-synuclein mice.
    Ann Neurol. 2020 Sep 29. doi: 10.1002/ana.25920.
    PubMed     Abstract available
    
    
    
87. SINGER W, Schmeichel AM, Shahnawaz M, Schmelzer JD, et al
    Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Ann Neurol. 2020;88:503-512.
    PubMed     Abstract available
    
    
    June 2020
88. IRMEN F, Horn A, Mosley P, Perry A, et al
    Left Prefrontal Connectivity Links Subthalamic Stimulation with Depressive Symptoms.
    Ann Neurol. 2020;87:962-975.
    PubMed     Abstract available
    
    
    
89. MONZON-SANDOVAL J, Poggiolini I, Ilmer T, Wade-Martins R, et al
    Human-Specific Transcriptome of Ventral and Dorsal Midbrain Dopamine Neurons.
    Ann Neurol. 2020;87:853-868.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge.